Association between response to triptans and response to erenumab: real-life data

• Published in: Journal of headache and pain Vol. 22; no. 1; pp. 1 - 6
• Main Authors: Frattale, Ilaria, Caponnetto, Valeria, Casalena, Alfonsina, Assetta, Maurizio, Maddestra, Maurizio, Marzoli, Fabio, Affaitati, Giannapia, Giamberardino, Maria Adele, Viola, Stefano, Gabriele, Amleto, Pistoia, Francesca, Cerone, Davide, Marini, Carmine, Sacco, Simona, Ornello, Raffaele
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 06.01.2021; Springer Nature B.V; BMC
• Subjects: Antibodies, Monoclonal, Humanized; Calcitonin; Calcitonin gene-related peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; CGRP; Drug therapy; Erenumab; Headache; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Migraine treatment; Monoclonal antibodies; Neurology; Pain management; Pain Medicine; Pathophysiology; Pharmacokinetics; Short Report; Triptans; Tryptamines; Triptans; Erenumab; CGRP; Migraine treatment

Background Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab. Main body In our study, consecutive patients referring to the Headache Centers of the Abruzzo regio...